Can aripiprazole (Abilify) cause supraventricular tachycardia (SVT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Abilify Cause SVT?

Aripiprazole (Abilify) is not documented to cause supraventricular tachycardia (SVT) specifically, but it can cause other cardiac arrhythmias including atrial fibrillation and tachycardia, particularly in overdose situations or in patients with risk factors.

Cardiac Effects of Aripiprazole

The FDA drug label for Abilify lists tachycardia and atrial fibrillation as documented cardiac effects in overdose cases, but does not specifically mention SVT 1. The label states that "other clinically important signs and symptoms observed in one or more patients with ABILIFY overdoses include...atrial fibrillation, bradycardia...hypertension, hypotension...QRS complex prolonged, QT prolonged...status epilepticus, and tachycardia" 1.

Evidence of Arrhythmias with Aripiprazole

Documented Arrhythmias:

  • Atrial fibrillation has been reported with therapeutic doses of aripiprazole, particularly in patients with concomitant risk factors (hypertension, cardiac dysfunction, rapid titration, high doses) 2
  • Severe arrhythmias have been documented in case reports, including a 13-year-old with schizophrenia who developed severe arrhythmia on aripiprazole 3
  • QRS widening can occur in overdose, particularly in CYP2D6 poor metabolizers, though this is distinct from SVT 4

QT Effects:

Low-quality evidence suggests that aripiprazole at therapeutic doses does not increase QT interval 5, which distinguishes it from some other antipsychotics that carry higher arrhythmia risk.

Clinical Context

Interestingly, one case report describes aripiprazole being used successfully to treat an adolescent who developed SVT while on olanzapine 6. This suggests aripiprazole may have a more favorable cardiac profile compared to some other antipsychotics.

Risk Factors for Cardiac Events

When cardiac arrhythmias do occur with aripiprazole, they are associated with:

  • Overdose situations (particularly massive overdoses in children causing prolonged effects) 7
  • Rapid titration and high doses 2
  • CYP2D6 poor metabolizer status (approximately 8% of Caucasians, 3-8% of Black/African Americans) 1, 4
  • Concomitant cardiac risk factors (hypertension, cardiac dysfunction, family history) 2

Clinical Recommendations

If a patient on aripiprazole develops palpitations or suspected arrhythmia:

  • Obtain an ECG immediately to characterize the rhythm
  • Look for QRS widening, QT prolongation, or specific arrhythmias (atrial fibrillation more likely than SVT)
  • Consider CYP2D6 metabolizer status if toxicity is suspected
  • Discontinue aripiprazole if temporally related to cardiac symptoms
  • Manage any documented SVT per standard protocols (vagal maneuvers, adenosine) 8, 9

Bottom line: While aripiprazole can cause tachycardia and atrial fibrillation, SVT is not a documented adverse effect in the FDA labeling or major case series. If SVT occurs in a patient on aripiprazole, consider alternative etiologies first.

References

Research

Aripiprazole-induced atrial fibrillation in a patient with concomitant risk factors.

Experimental and clinical psychopharmacology, 2018

Research

Prolonged QRS Widening After Aripiprazole Overdose.

Pediatric emergency care, 2019

Research

Supraventricular Tachycardia in an Adolescent with Acute Psychotic Disorder Treated with Olanzapine: A Rare Event Managed with Aripiprazole.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2026

Research

Abilifright: A Case Report of Massive Aripiprazole Overdose in a Toddler.

Clinical practice and cases in emergency medicine, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.